SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                  --------------------------------------------


                                    FORM 8-K

                                 CURRENT REPORT

                     PURSUANT TO SECTION 13 OR 15(D) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

        Date of report (Date of earliest event reported): April 14, 2004
                                                          --------------

                               CYTOGEN CORPORATION
              ----------------------------------------------------
               (Exact Name of Registrant as Specified in Charter)

         Delaware                       000-14879                 222322400
- ----------------------------     -----------------------     -------------------
(State or Other Jurisdiction     (Commission File Number)     (I.R.S. Employer
     of Incorporation)                                       Identification No.)


650 College Road East, CN 5308, Suite 3100, Princeton, NJ                08540
- ---------------------------------------------------------             ----------
       (Address of Principal Executive Offices)                       (Zip Code)

       Registrant's telephone number, including area code: (609) 750-8200
                                                           --------------




ITEM 5.  OTHER EVENTS.

     As  previously  disclosed  in  the  Company's  periodic  filings  with  the
Securities and Exchange Commission, the Company is involved in litigation in the
United States  District  Court for the District of New Jersey in an action filed
by M.  David  Goldenberg  and  Immunomedics,  Inc.  relating  to  the  Company's
PROSTASCINT  product.  The Company  moved for summary  judgment  dismissing  the
action, which motion was granted on April 29, 2003. That dismissal was appealed,
and oral argument on the appeal was held on March 2, 2004.  The appellate  court
has not  indicated  when it  expects  to  issue a  ruling;  however,  given  the
uncertainty  associated with  litigation,  the Company cannot give any assurance
that the litigation could not result in a material expenditure to the Company.

     In connection with a recent review of certain of the Company's intellectual
property,  it was determined  that the Company was the  recipient,  beginning in
1998, of correspondence  from legal counsel  representing the former employer of
Dr. Julius Horoszewicz,  the sole inventor on the principal United States patent
covering PROSTASCINT.  Such correspondence alleged that the patent rights to Dr.
Horoszewicz's discoveries were the property of such former employer and that Dr.
Horoszewicz had no right to assign them to the Company.  The Company  vigorously
disputed those  allegations,  and the Company has no record of the matter having
been pursued by such former employer subsequent to August 2000.

     The  Company  believes  that  in view of the  marketing  of the  technology
covered  by the patent  through  the sale of  PROSTASCINT  by the  Company,  the
Company's  right to use the underlying  technology in its continuing  production
and sale of  PROSTASCINT  should not be at risk.  However,  if such  claims were
reasserted,  and if it were to be concluded that Dr.  Horoszewicz in fact had no
right to assign the patent to the  Company,  a court  could  determine  that the
Company  has no right to use the  technology  covered  by the patent or that any
royalties  paid by or payable by the Company in respect of the use of the patent
should have been paid in the past,  and should in the future be payable,  to Dr.
Horoszewicz's former employer in lieu of Dr. Horoszewicz. The amount of any such
payments,  and the Company's liability for them, is not presently  determinable,
and the Company  cannot give any assurance that an adverse  determination  could
not result in a material  expenditure to the Company or have a material  adverse
effect on the Company's financial condition.

     Under the Company's  agreement with Dr.  Horoszewicz,  Dr.  Horoszewicz has
agreed to indemnify the Company against  damages based upon Cytogen's  ownership
of the rights assigned by Dr. Horoszewicz.




                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

                                    CYTOGEN CORPORATION


                                    By: /s/ Michael D. Becker
                                        ----------------------------------------
                                        Michael D. Becker
                                        President and Chief Executive
                                        Officer

Dated:   April 14, 2004